NCT07494448 2026-03-27
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting
Clinical Trials
7 trialsNCT07461454 2026-03-10
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
NCT07441512 2026-03-02
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07406542 2026-02-12
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07333937 2026-01-12
NETHER
Xijing Hospital
Phase 2 Not yet recruiting
NCT07255612 2025-12-01
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07205185 2025-10-03
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
Fudan University
Phase 2 Not yet recruiting